Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
AssigneeRemedor Biomed Ltd.
InventorSaher HAMED
Life of this patent
Estimating the term…
Abstract
A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
Claims18
A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm2 tissue of Erythropoietin and about 100-300 μg per cm2 tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject.
A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm2 tissue of Erythropoietin and about 100-300 μg per cm2 tissue of Fibronectin, thereby treating ischemia in the subject.
A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration.
Dependencies are inferred from the claim text.